JORR
Journal of Orthopedics Research and Rehabilitation

The Journal of Orthopedics Research and Rehabilitation welcomes scholarly papers in orthopaedic surgery, physical therapy and rehabilitation, physiotherapy, neurology and clinic anesthesiology and reanimation.

eISSN: 2980-0560
Creative Commons CC BY-NC-ND 4.0 International License.

Online Manuscript System

Index
Original Article
Investigation of the effect of fibromyalgia frequency on quality of life, daily living activities, disease perception, and clinical parameters in patients with chronic kidney failure undergoing dialysis treatment
Abstract
Aims: Fibromyalgia syndrome (FMS) may be under-recognized in hemodialysis populations, where chronic inflammation, musculoskeletal complaints, and reduced health-related quality of life (HRQoL) frequently overlap. This study evaluated the prevalence of FMS in hemodialysis and examined its associations with pain, activities of daily living, HRQoL, and routine dialysis/laboratory parameters.
Methods: In this cross-sectional study, 127 adults were analyzed: 69 patients receiving maintenance hemodialysis (dialysis group) and 58 non-dialysis patients with FMS diagnosed using the ACR 2011 criteria and the 2016 revision (FMS group). Within the dialysis cohort, participants were stratified as FMS(+) (n=38) and FMS(–) (n=31). Pain intensity was assessed using a 0–10 Visual Analog Scale (VAS), functional independence with Katz Activities of Daily Living (ADL), and HRQoL with SF-36 (domain scores and summary measures). Dialysis/laboratory variables included pre- and post-dialysis blood urea nitrogen (BUN), Kt/V, parathyroid hormone (PTH), sodium (Na), and calcium (Ca). The primary outcome was SF-36 Role Limitations–Emotional. Multivariable logistic regression (dialysis cohort) and ROC analyses were performed to evaluate predictors of FMS.
Results: The prevalence of FMS within the hemodialysis cohort was 55.1% (38/69). Between-group comparisons (dialysis vs FMS) showed higher BMI in the FMS group (28.7 ± 4.8 vs 25.3 ± 5.7; p<0.001), while VAS pain and Katz ADL scores were similar. SF-36 summary scores were higher in the FMS group (PCS, p=0.039; MCS, p=0.008; Total, p=0.012). At the domain level, General Health (45.1 ± 16.1 vs 38.6 ± 13.5; p=0.015) and Role Limitations–Emotional (62.0 ± 40.2 vs 28.5 ± 38.4; p<0.001) were higher in the FMS group. Within the dialysis cohort, Role Limitations–Emotional remained higher in FMS(+) patients (36.8 ± 39.3 vs 18.2 ± 35.3; p=0.024), and post-dialysis BUN was higher in FMS(+) patients (27.5 ± 13.4 vs 19.8 ± 4.3; p=0.008). In multivariable analysis, only post-dialysis BUN was independently associated with FMS (OR=1.10; 95% CI 1.02–1.19; p=0.012). Discrimination was moderate for post-dialysis BUN alone (AUC=0.684) and improved slightly with the multivariable model (AUC=0.726).
Conclusion: FMS was common among hemodialysis patients and was associated with differences in emotional role functioning and higher post-dialysis BUN. These findings support a multidimensional approach to screening in dialysis care that integrates symptom-based FMS assessment with HRQoL profiling and selected biochemical signals.

Keywords : Fibromyalgia, hemodialysis, chronic kidney disease, SF-36, activities of daily living, quality of life

Download Article


1. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. doi:10.1001/jama.2014.3266
2. Findeisen K, Guymer E, Littlejohn G. Neuroinflammatory and immunological aspects of fibromyalgia. Brain Sci. 2025;15(2):206. doi: 10.3390/brainsci15020206
3. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. doi:10.1007/s11916-013-0356-5
4. Troutman AD, Arroyo E, Lim K, Moorthi RN, Avin KG. Skeletal muscle complications in chronic kidney disease. Curr Osteoporos Rep. 2022;20(6):410-421. doi:10.1007/s11914-022-00751-w
5. Çağlıyan Türk A, Özkurt S, Doğan İ, Şahin F. Fibromyalgia syndrome and related factors in hemodialysis, peritoneal dialysis, and renal transplant patients: a cross-sectional study. Arch Rheumatol. 2021;37(1): 67-76. doi:10.46497/ArchRheumatol.2022.8227
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
7. Kocyigit I, Eroglu E, Unal A, et al. Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol. 2013;26(2):358-365. doi:10.5301/jn.5000152
8. Wang Y, Gao L. Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease. Front Pharmacol. 2022; 13:800950. doi:10.3389/fphar.2022.800950
9. Feroze U, Noori N, Kovesdy CP, et al. Quality-of-life and mortality in hemodialysis patients: roles of race and nutritional status. Clin J Am Soc Nephrol. 2011;6(5):1100-1111. doi:10.2215/CJN.07690910
10. Arnold LM, Bennett RM, Crofford LJ, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611-628. doi:10.1016/j.jpain.2018.10.008
11. Galvez-Sánchez CM, Reyes Del Paso GA. Diagnostic criteria for fibromyalgia: critical review and future perspectives. J Clin Med. 2020;9 (4):1219. doi:10.3390/jcm9041219
12. Häuser W, Bernardy K, Arnold B, Offenbächer M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009;61(2):216-224. doi:10.1002/art.24276
13. National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884-9 30. doi:10.1053/j.ajkd.2015.07.015
14. Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018;10(1):33. doi:10.3390/toxins10010033
15. Magagnoli L, Cozzolino M, Evans M, et al. Association between chronic kidney disease-mineral and bone disorder biomarkers and symptom burden in older patients with advanced chronic kidney disease: results from the EQUAL study. Clin J Am Soc Nephrol. 2024;19(10):1240-1252. doi:10.215/CJN.0000000000000510
16. Bouchachi FZ, Al Wachami N, Iderdar Y, Arraji M, Elgot A, Chahboune M. Bio-sociological and clinical factors of chronic pain and pain interference in patients undergoing hemodialysis: a cross-sectional study. BMC Nephrol. 2025;26(1):83. doi:10.1186/s12882-025-03987-7
17. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343-366. doi:10.1097/ALN.0000000000002130
18. Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71. doi:10.1186/1477-7525-10-71
19. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-881. doi:10. 1016/j.ajkd.2003.07.016
20. Şirali, SK, Büberci R. The relationship between fibromyalgia syndrome and inflammation parameters in hemodialysis patients. Eur Res J. 2024; 1-8. doi:10.18621/eurj.1361155
21. Bossola M, Di Stasio E, Marzetti E, De Lorenzis K, Pepe G, Vulpio C. Fatigue is associated with high prevalence and severity of physical and emotional symptoms in patients on chronic hemodialysis. Int Urol Nephrol. 2018;50(7):1341-1346. doi:10.1007/s11255-018-1875-0
22. Çağlıyan Türk A, Özkurt S, Doğan İ, Şahin F. Fibromyalgia syndrome and related factors in hemodialysis, peritoneal dialysis, and renal transplant patients: a cross-sectional study. Arch Rheumatol. 2021;37(1): 67-76. doi:10.46497/ArchRheumatol.2022.8227
23. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724
24. Tseng HM, Lu JF, Gandek B. Cultural issues in using the SF-36 Health Survey in Asia: results from Taiwan. Health Qual Life Outcomes. 2003;1: 72. doi:10.1186/1477-7525-1-72
25. Fukuhara S, Lopes AA, Bragg-Gresham JL, et al. Health-related quality of life among dialysis patients on three continents: the dialysis outcomes and practice patterns study. Kidney Int. 2003;64(5):1903-1910. doi:10.1046/j.1523-1755.2003.00289.x
26. Elliott BA, Gessert CE, Larson PM, Russ TE. Shifting responses in quality of life: people living with dialysis. Qual Life Res. 2014;23(5):1497-1504. doi:10.1007/s11136-013-0600-9
Article available in :
Volume 4, Issue 1, 2026
Page : 16-21
https://doi.org/10.51271/JORR-0064
Article Information
Received : 02 Oca 2026
Accepted : 30 Oca 2026
Published : 31 Oca 2026
Corresponding Author :

Turgut Kültür: Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkiye

[email protected]
Citation : Öztürk H, Öztürk ZN, Varlıbaş A, Ceyhan Z, Kültür T, Çifci A. Investigation of the effect of fibromyalgia frequency on quality of life, daily living activities, disease perception, and clinical parameters in patients with chronic kidney failure undergoing dialysis treatment. J Orthop Res Rehabil. 2026;4(1):16-21.

Read: 53
Download : 34
Cited: 0
_Footer